Report Detail
Global Hepatocellular Carcinoma Drugs Market Professional Survey Report 2019
- RnM3747659 |
- 14 September, 2019 |
- Global |
- 113 Pages |
- QYResearch |
- Pharma & Healthcare
HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.
The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.
The global Hepatocellular Carcinoma Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Hepatocellular Carcinoma Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hepatocellular Carcinoma Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Hepatocellular Carcinoma Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Hepatocellular Carcinoma Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Bayer
Eli Lilly
Johnson and Johnson
Pfizer
Bristol-Myers Squibb
Celgene
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck
Novartis
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Brachytherapy
Chemotherapy
Local Ablation Therapy
Segment by Application
Hospitals
Clinics
Cancer Rehabilitation Centers
Table of Contents
Executive Summary
1 Industry Overview of Hepatocellular Carcinoma Drugs
- 1.1 Definition of Hepatocellular Carcinoma Drugs
- 1.2 Hepatocellular Carcinoma Drugs Segment by Type
- 1.2.1 Global Hepatocellular Carcinoma Drugs Production Growth Rate Comparison by Types (2014-2025)
- 1.2.2 Brachytherapy
- 1.2.3 Chemotherapy
- 1.2.4 Local Ablation Therapy
- 1.3 Hepatocellular Carcinoma Drugs Segment by Applications
- 1.3.1 Global Hepatocellular Carcinoma Drugs Consumption Comparison by Applications (2014-2025)
- 1.3.2 Hospitals
- 1.3.3 Clinics
- 1.3.4 Cancer Rehabilitation Centers
- 1.4 Global Hepatocellular Carcinoma Drugs Overall Market
- 1.4.1 Global Hepatocellular Carcinoma Drugs Revenue (2014-2025)
- 1.4.2 Global Hepatocellular Carcinoma Drugs Production (2014-2025)
- 1.4.3 North America Hepatocellular Carcinoma Drugs Status and Prospect (2014-2025)
- 1.4.4 Europe Hepatocellular Carcinoma Drugs Status and Prospect (2014-2025)
- 1.4.5 China Hepatocellular Carcinoma Drugs Status and Prospect (2014-2025)
- 1.4.6 Japan Hepatocellular Carcinoma Drugs Status and Prospect (2014-2025)
- 1.4.7 Southeast Asia Hepatocellular Carcinoma Drugs Status and Prospect (2014-2025)
- 1.4.8 India Hepatocellular Carcinoma Drugs Status and Prospect (2014-2025)
2 Manufacturing Cost Structure Analysis
- 2.1 Raw Material and Suppliers
- 2.2 Manufacturing Cost Structure Analysis of Hepatocellular Carcinoma Drugs
- 2.3 Manufacturing Process Analysis of Hepatocellular Carcinoma Drugs
- 2.4 Industry Chain Structure of Hepatocellular Carcinoma Drugs
3 Development and Manufacturing Plants Analysis of Hepatocellular Carcinoma Drugs
- 3.1 Capacity and Commercial Production Date
- 3.2 Global Hepatocellular Carcinoma Drugs Manufacturing Plants Distribution
- 3.3 Major Manufacturers Technology Source and Market Position of Hepatocellular Carcinoma Drugs
- 3.4 Recent Development and Expansion Plans
4 Key Figures of Major Manufacturers
- 4.1 Hepatocellular Carcinoma Drugs Production and Capacity Analysis
- 4.2 Hepatocellular Carcinoma Drugs Revenue Analysis
- 4.3 Hepatocellular Carcinoma Drugs Price Analysis
- 4.4 Market Concentration Degree
5 Hepatocellular Carcinoma Drugs Regional Market Analysis
- 5.1 Hepatocellular Carcinoma Drugs Production by Regions
- 5.1.1 Global Hepatocellular Carcinoma Drugs Production by Regions
- 5.1.2 Global Hepatocellular Carcinoma Drugs Revenue by Regions
- 5.2 Hepatocellular Carcinoma Drugs Consumption by Regions
- 5.3 North America Hepatocellular Carcinoma Drugs Market Analysis
- 5.3.1 North America Hepatocellular Carcinoma Drugs Production
- 5.3.2 North America Hepatocellular Carcinoma Drugs Revenue
- 5.3.3 Key Manufacturers in North America
- 5.3.4 North America Hepatocellular Carcinoma Drugs Import and Export
- 5.4 Europe Hepatocellular Carcinoma Drugs Market Analysis
- 5.4.1 Europe Hepatocellular Carcinoma Drugs Production
- 5.4.2 Europe Hepatocellular Carcinoma Drugs Revenue
- 5.4.3 Key Manufacturers in Europe
- 5.4.4 Europe Hepatocellular Carcinoma Drugs Import and Export
- 5.5 China Hepatocellular Carcinoma Drugs Market Analysis
- 5.5.1 China Hepatocellular Carcinoma Drugs Production
- 5.5.2 China Hepatocellular Carcinoma Drugs Revenue
- 5.5.3 Key Manufacturers in China
- 5.5.4 China Hepatocellular Carcinoma Drugs Import and Export
- 5.6 Japan Hepatocellular Carcinoma Drugs Market Analysis
- 5.6.1 Japan Hepatocellular Carcinoma Drugs Production
- 5.6.2 Japan Hepatocellular Carcinoma Drugs Revenue
- 5.6.3 Key Manufacturers in Japan
- 5.6.4 Japan Hepatocellular Carcinoma Drugs Import and Export
- 5.7 Southeast Asia Hepatocellular Carcinoma Drugs Market Analysis
- 5.7.1 Southeast Asia Hepatocellular Carcinoma Drugs Production
- 5.7.2 Southeast Asia Hepatocellular Carcinoma Drugs Revenue
- 5.7.3 Key Manufacturers in Southeast Asia
- 5.7.4 Southeast Asia Hepatocellular Carcinoma Drugs Import and Export
- 5.8 India Hepatocellular Carcinoma Drugs Market Analysis
- 5.8.1 India Hepatocellular Carcinoma Drugs Production
- 5.8.2 India Hepatocellular Carcinoma Drugs Revenue
- 5.8.3 Key Manufacturers in India
- 5.8.4 India Hepatocellular Carcinoma Drugs Import and Export
6 Hepatocellular Carcinoma Drugs Segment Market Analysis (by Type)
- 6.1 Global Hepatocellular Carcinoma Drugs Production by Type
- 6.2 Global Hepatocellular Carcinoma Drugs Revenue by Type
- 6.3 Hepatocellular Carcinoma Drugs Price by Type
7 Hepatocellular Carcinoma Drugs Segment Market Analysis (by Application)
- 7.1 Global Hepatocellular Carcinoma Drugs Consumption by Application
- 7.2 Global Hepatocellular Carcinoma Drugs Consumption Market Share by Application (2014-2019)
8 Hepatocellular Carcinoma Drugs Major Manufacturers Analysis
- 8.1 Bayer
- 8.1.1 Bayer Hepatocellular Carcinoma Drugs Production Sites and Area Served
- 8.1.2 Bayer Product Introduction, Application and Specification
- 8.1.3 Bayer Hepatocellular Carcinoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.1.4 Main Business and Markets Served
- 8.2 Eli Lilly
- 8.2.1 Eli Lilly Hepatocellular Carcinoma Drugs Production Sites and Area Served
- 8.2.2 Eli Lilly Product Introduction, Application and Specification
- 8.2.3 Eli Lilly Hepatocellular Carcinoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.2.4 Main Business and Markets Served
- 8.3 Johnson and Johnson
- 8.3.1 Johnson and Johnson Hepatocellular Carcinoma Drugs Production Sites and Area Served
- 8.3.2 Johnson and Johnson Product Introduction, Application and Specification
- 8.3.3 Johnson and Johnson Hepatocellular Carcinoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.3.4 Main Business and Markets Served
- 8.4 Pfizer
- 8.4.1 Pfizer Hepatocellular Carcinoma Drugs Production Sites and Area Served
- 8.4.2 Pfizer Product Introduction, Application and Specification
- 8.4.3 Pfizer Hepatocellular Carcinoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.4.4 Main Business and Markets Served
- 8.5 Bristol-Myers Squibb
- 8.5.1 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Production Sites and Area Served
- 8.5.2 Bristol-Myers Squibb Product Introduction, Application and Specification
- 8.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.5.4 Main Business and Markets Served
- 8.6 Celgene
- 8.6.1 Celgene Hepatocellular Carcinoma Drugs Production Sites and Area Served
- 8.6.2 Celgene Product Introduction, Application and Specification
- 8.6.3 Celgene Hepatocellular Carcinoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.6.4 Main Business and Markets Served
- 8.7 F. Hoffmann-la Roche
- 8.7.1 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Production Sites and Area Served
- 8.7.2 F. Hoffmann-la Roche Product Introduction, Application and Specification
- 8.7.3 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.7.4 Main Business and Markets Served
- 8.8 Gilead
- 8.8.1 Gilead Hepatocellular Carcinoma Drugs Production Sites and Area Served
- 8.8.2 Gilead Product Introduction, Application and Specification
- 8.8.3 Gilead Hepatocellular Carcinoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.8.4 Main Business and Markets Served
- 8.9 GlaxoSmithKline
- 8.9.1 GlaxoSmithKline Hepatocellular Carcinoma Drugs Production Sites and Area Served
- 8.9.2 GlaxoSmithKline Product Introduction, Application and Specification
- 8.9.3 GlaxoSmithKline Hepatocellular Carcinoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.9.4 Main Business and Markets Served
- 8.10 Merck
- 8.10.1 Merck Hepatocellular Carcinoma Drugs Production Sites and Area Served
- 8.10.2 Merck Product Introduction, Application and Specification
- 8.10.3 Merck Hepatocellular Carcinoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.10.4 Main Business and Markets Served
- 8.11 Novartis
9 Development Trend of Analysis of Hepatocellular Carcinoma Drugs Market
- 9.1 Global Hepatocellular Carcinoma Drugs Market Trend Analysis
- 9.1.1 Global Hepatocellular Carcinoma Drugs Market Size (Volume and Value) Forecast 2019-2025
- 9.2 Hepatocellular Carcinoma Drugs Regional Market Trend
- 9.2.1 North America Hepatocellular Carcinoma Drugs Forecast 2019-2025
- 9.2.2 Europe Hepatocellular Carcinoma Drugs Forecast 2019-2025
- 9.2.3 China Hepatocellular Carcinoma Drugs Forecast 2019-2025
- 9.2.4 Japan Hepatocellular Carcinoma Drugs Forecast 2019-2025
- 9.2.5 Southeast Asia Hepatocellular Carcinoma Drugs Forecast 2019-2025
- 9.2.6 India Hepatocellular Carcinoma Drugs Forecast 2019-2025
- 9.3 Hepatocellular Carcinoma Drugs Market Trend (Product Type)
- 9.4 Hepatocellular Carcinoma Drugs Market Trend (Application)
- 10.1 Marketing Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.3 Hepatocellular Carcinoma Drugs Customers
11 Market Dynamics
- 11.1 Market Trends
- 11.2 Opportunities
- 11.3 Market Drivers
- 11.4 Challenges
- 11.5 Influence Factors
12 Conclusion
13 Appendix
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Hepatocellular Carcinoma Drugs. Industry analysis & Market Report on Hepatocellular Carcinoma Drugs is a syndicated market report, published as Global Hepatocellular Carcinoma Drugs Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Hepatocellular Carcinoma Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
